From our Facebook page ….. Max Latalliade

New Post Public Reply Private Reply Replies (1) Message Board
FKAdamF.
775
From our Facebook page ….. Max Latalliade https://m.facebook.com/groups/622470341583807...tid=wwXIfr
Max Latalliade….This is why I joined the Gates Foundation!
On a recent trip with colleagues from the Gates Foundation and the University of Washington, we visited a remote village in Uganda to evaluate clinical trial sites for a novel long-acting agent. It was in this far-reaching gold mining community that I was warmly embraced by the most beautiful children. Yet, due to the local social, behavioral, and economic challenges, HIV transmission remains high.
After nearly 20 years as a physician scientist and researcher in Pharma-successfully developing several antivirals and antiretrovirals for HIV and HCV-I've had the privilege of advancing the science and strategy behind long-acting agents for HIV treatment and PrEP. Now, I've joined the Gates Foundation with a clear and ambitious goal: ending the HIV epidemic.
Yes, it's a big goal. But with current and near-term long-acting antiretrovirals-whether oral or injectables-we have a real opportunity to halt HIV transmission and make strides toward ending the epidemic.
These children deserve a future without the looming threat of HIV, a condition that is currently lifelong and often fatal in communities like theirs. Together, let's push the boundaries of what's possible and finish the job!

We have a great team behind us and they all have the best of intentions.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Gnosis Lab's Grand Re-Opening: A New Era for Diagnostics

Updated Category News Views 260

Gnosis Lab Grand Re-Opening Celebration Gnosis, a modern diagnostic laboratory previously known as Mountain View Medical Laboratory, is excited to announce its grand re-opening at its flagship location. This event signifies a crucial transition for the lab as it seeks to blend years of reliable community service with a fresh identity and enhanced capabilities. Commitment...

Continue Reading
New Propane Contract Boosts Titan NRG (TTNN) Growth

Updated Category Stocks Views 404

Titan NRG, Inc. Announces Major Propane Contract Secured Titan NRG, Inc. (OTC: TTNN) has a big contract for the 150,000 gallons of propane supply. Given to one of its subsidiaries, this contract represents a significant turning point for the business. Under this contract, propane will be delivered over the next year to a southern Arizona reservation. Crucially in securing...

Continue Reading
Bitcoin Price Decline: Impact of DOJ and Economic Conditions

Updated Category News Views 259

Bitcoin Price Experiences a Notable Decline Bitcoin has recently faced a serious downturn, falling to around $93,925 as fears surrounding U.S. interest rate changes and potential government sales of Bitcoin emerged. This has created a concerning environment for cryptocurrency investors, highlighting the volatility of digital assets. Market Sentiment and Economic Shifts...

Continue Reading
Cogitate and One Inc Team Up to Revolutionize Payments

Updated Category News Views 169

Cogitate Partners with One Inc to Transform Digital Payments -Customers Enjoy a Seamless Experience by Unifying All Payment Flows into One Comprehensive Platform- Cogitate, a provider of cloud-native core policy, billing, and claims applications for insurers, is excited to announce its partnership with One Inc, the leading digital payments network specifically for the...

Continue Reading
Alnylam Pharmaceuticals Achieves New Stock Milestone of $287.88

Updated Category News Views 74

Alnylam Pharmaceuticals Reaches Record Stock Price Alnylam Pharmaceuticals Inc. has recently made headlines after its stock price reached a remarkable all-time high of $287.88. This surge demonstrates a substantial increase in investor confidence, bolstered by an impressive 1-year change of 71.84% in the company's stock. Known for its groundbreaking work in RNA...

Continue Reading